We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Reneuron Group Plc | LSE:RENE | London | Ordinary Share | GB00BF5G6K95 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.05 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 530k | -5.41M | -0.0946 | -0.32 | 1.74M |
TIDMRENE
RNS Number : 0263S
ReNeuron Group plc
12 March 2021
ReNeuron Group plc
("ReNeuron" or the "Company")
Directorate change
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that Michael Hunt, an executive director of the Company and its current Chief Financial Officer, has yesterday resigned from the Company in order to pursue other projects. Mr Hunt joined the Board in early 2001 and will remain with the Company until the end of May to facilitate an orderly transition to his successor, when appointed. The Company has initiated a search for Mr Hunt's replacement and a further announcement will be made in due course.
Mr Hunt commented:
"After twenty years at the Company, and with the business now in a much stronger financial position, it is the right time for me to move on to new challenges. I am proud to have contributed to ReNeuron's progression to be one of the leading players in the gene and cell therapy sector, and I wish the Company and colleagues every future success."
Olav Hellebø, Chief Executive Officer, commented:
"With tenures over the years as both CFO and CEO of the Company, Michael has played a key role in the development of ReNeuron into the exciting business that it is today. On behalf of ReNeuron, I would like to thank Michael for his very significant contribution to the Company and wish him well in his future endeavours."
ENDS
Contacts:
ReNeuron www.reneuron.com/investors Olav Hellebø, Chief Executive Via Walbrook PR Officer Michael Hunt, Chief Financial Officer Stifel Nicolaus Europe Limited (NOMAD and Joint Broker) Ben Maddison, Stewart Wallace +44 (0)20 7710 7600 Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656 James Reeve/George Payne (Corporate Finance) Tim Sohal (Sales & Corporate Broking) Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7407 Paul McManus, Alice Woodings 804 654
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.
ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the brain. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make any tissue cells of choice; in-house programmes are focused on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
BOABIGDXSSBDGBB
(END) Dow Jones Newswires
March 12, 2021 02:00 ET (07:00 GMT)
1 Year Reneuron Chart |
1 Month Reneuron Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions